☆ 4.5 Article

mTORC1 activation in childhood ependymoma and response to sirolimus

JOURNAL OF NEURO-ONCOLOGY (2011)

Journal

JOURNAL OF NEURO-ONCOLOGY

Volume 103, Issue 3, Pages 797-801

Publisher

SPRINGER

DOI: 10.1007/s11060-010-0455-7

Keywords

Ependymoma; Sirolimus; Rapamycin; mTORC1

Categories

Oncology Clinical Neurology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Recurrent ependymomas are considered rarely responsive to chemotherapy and often have a dismal prognosis after tumor progression. Below is a brief report of a 6 year old child with a multiply progressive ependymoma whose tumor had a near complete response to sirolimus that was durable for 18 months. Immunohistochemistry for phosphorylated S6, which has been reported to be associated with tumor sensitivity to mTORC1 inhibitors, was positive in this patient's tumor.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Endocrinology & Metabolism

MTORC1 inhibition drives crinophagic degradation of glucagon

Sangam Rajak, Sherwin Xie, Archana Tewari, Sana Raza, Yajun Wu, Boon-Huat Bay, Paul M. Yen, Rohit A. Sinha

Summary: This study identified a novel crinophagic mechanism regulated by MTORC1 signaling for intracellular turnover of glucagon in pancreatic alpha cells.

MOLECULAR METABOLISM (2021)

Add to Collection

Editorial Material Cell Biology

MTORC1-dependent crinophagy regulates glucagon content in pancreatic α-cells

Sangam Rajak, Paul M. Yen, Rohit A. Sinha

Summary: Crinophagy, the intracellular degradation of hormone-containing secretory vesicles by lysosomes, plays a critical role in regulating hormone secretion. Inhibition of MTORC1 induces crinophagy-mediated degradation of glucagon, leading to decreased secretion in response to hypoglycemia, suggesting that modulating crinophagy could be a novel therapeutic strategy for endocrine and metabolic disorders.

AUTOPHAGY (2021)

Add to Collection

Article Cell Biology

mTORC1-Mediated Angiogenesis is Required for the Development of Rosacea

Qinqin Peng, Ke Sha, Yingzi Liu, Mengting Chen, San Xu, Hongfu Xie, Zhili Deng, Ji Li

Summary: The study found that angiogenesis was enhanced in both rosacea patients and LL37-induced rosacea-like mice, with inhibition of angiogenesis alleviating rosacea-like features. Activation of mTORC1 in endothelial cells was observed in the lesional skin, and inhibiting mTORC1 decreased angiogenesis and blocked rosacea development. In vitro results showed that inhibiting mTORC1 signaling significantly decreased LL37-induced tube formation of human endothelial cells, suggesting that targeting angiogenesis may be a potential therapy for rosacea.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Review Food Science & Technology

Regulation of Adipocyte and Macrophage Functions by mTORC1 and 2 in Metabolic Diseases

William T. Festuccia

Summary: Evidence suggests that lipotoxicity and inflammation are key factors linking adipose tissue dysfunction to metabolic diseases, with mTOR playing a crucial role in regulating adipocyte and macrophage function. Studies reviewed here show that optimal levels of mTORC1 activity are necessary for lipogenic actions in adipocytes, while mTORC1 also regulates polarization in macrophages. On the other hand, mTORC2 promotes glucose uptake and lipogenesis in adipocytes while dampening macrophage inflammatory response.

MOLECULAR NUTRITION & FOOD RESEARCH (2021)

Add to Collection

Article Biochemistry & Molecular Biology

mTORC1 activity negatively regulates human hair follicle growth and pigmentation

Takahiro Suzuki, Jeremy Cheret, Fernanda Dinelli Scala, Aysun Akhundlu, Jennifer Gherardini, Dana-Lee Demetrius, James D. B. O'Sullivan, Gorana Kuka Epstein, Alan J. Bauman, Constantinos Demetriades, Ralf Paus

Summary: Dysregulation of mTORC1 activity is closely related to aging, cancer, and genetic disorders. In this study, the role of mTORC1 in human hair follicles was investigated, revealing its negative regulation on hair growth and pigmentation. Inhibition of mTORC1 stimulated hair follicle growth and pigmentation, while knockdown of the TSC2 gene reduced pigmentation. These findings suggest that pharmacological inhibition of mTORC1 could be a potential strategy for managing hair loss and depigmentation disorders.

EMBO REPORTS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Reciprocal signaling between mTORC1 and MNK2 controls cell growth and oncogenesis

Jianling Xie, Kaikai Shen, Ashley T. Jones, Jian Yang, Andrew R. Tee, Ming Hong Shen, Mengyuan Yu, Swati Irani, Derick Wong, James E. Merrett, Roman Lenchine, Stuart De Poi, Kirk B. Jensen, Paul J. Trim, Marten F. Snel, Makoto Kamei, Sally Kim Martin, Stephen Fitter, Shuye Tian, Xuemin Wang, Lisa M. Butler, Andrew C. W. Zannettino, Christopher G. Proud

Summary: This study uncovers a novel feedback loop in which mTORC1 represses MNK2 activity and oncogenic signaling through eIF4E phosphorylation, providing insights into the reciprocal regulation of these two oncogenic pathways.

CELLULAR AND MOLECULAR LIFE SCIENCES (2021)

Add to Collection

Article Medicine, Research & Experimental

A positive feedback loop between mTORC1 and cathelicidin promotes skin inflammation in rosacea

Zhili Deng, Mengting Chen, Yingzi Liu, San Xu, Yuyan Ouyang, Wei Shi, Dan Jian, Ben Wang, Fangfen Liu, Jinmao Li, Qian Shi, Qinqin Peng, Ke Sha, Wenqin Xiao, Tangxiele Liu, Yiya Zhang, Hongbing Zhang, Qian Wang, Lunquan Sun, Hongfu Xie, Ji Li

Summary: The study demonstrates that mTORC1 signaling is hyperactivated in the skin of rosacea patients and mouse model, blocking mTORC1 signaling can alleviate rosacea symptoms, while its hyperactivation can worsen the condition.

EMBO MOLECULAR MEDICINE (2021)

Add to Collection

Article Cell Biology

Autophagy preserves hematopoietic stem cells by restraining MTORC1-mediated cellular anabolism

Mariana Borsa, Sandrine Obba, Felix C. Richter, Hanlin Zhang, Thomas Riffelmacher, Joana Carrelha, Ghada Alsaleh, Sten Eirik W. Jacobsen, Anna Katharina Simon

Summary: This study investigates the importance of autophagy in stem cells and finds that autophagy deficiency leads to stem cell loss and bone marrow failure, while inhibition of MTOR can rescue this loss and improve stem cell function.

AUTOPHAGY (2023)

Add to Collection

Article Medicine, Research & Experimental

Cytoplasmic RNA quality control failure engages mTORC1-mediated autoinflammatory disease

Kun Yang, Jie Han, Mayumi Asada, Jennifer G. Gill, Jason Y. Park, Meghana N. Sathe, Jyothsna Gattineni, Tracey Wright, Christian A. Wysocki, M. Teresa de la Morena, Luis A. Garza, Nan Yan

Summary: Inborn errors of nucleic acid metabolism often cause aberrant activation of nucleic acid sensing pathways, leading to autoimmune or autoinflammatory diseases. This study demonstrates the physiological function of SKIV2L in mammals. Skiv2l deficiency disrupts the homeostasis of epidermis and T cells, resulting in skin inflammation and hair abnormality. SKIV2L loss activates the mTORC1 pathway and drives autoinflammatory disease.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Add to Collection

Article Rheumatology

Renal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis

Zhaomin Mao, Ying Tan, Juan Tao, Linlin Li, Hui Wang, Feng Yu, Andras Perl, Minghui Zhao

Summary: This study evaluated the activation of mammalian target of rapamycin (mTOR) in renal tissue of LN patients. The activation of mTORC1/2 was found to be significantly increased in different cell types of LN patients compared to controls, and mTORC1 activation was strongly associated with clinical and pathological indicators of LN. The study also identified mTORC1 activation as a prognostic marker in LN patients.

RHEUMATOLOGY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Regulating T Cell Population Alleviates SLE by Inhibiting mTORC1/C2 in MRL/lpr Mice

Dongya Zhang, Meiling Wang, Guoping Shi, Peng Pan, Jianjian Ji, Pengfei Li

Summary: The study compared the therapeutic effects of INK128 and rapamycin on lupus mice, showing that INK128 more effectively alleviated splenomegaly, renal inflammation, and damage in SLE, as well as restoring T-cell dysfunction, by suppressing both mTORC1 and mTORC2 activities in T cells, whereas rapamycin only inhibited mTORC1 activity.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Immunology

mTORC1 Inhibition Protects Human Regulatory T Cells From Granzyme-B-Induced Apoptosis

Siawosh K. Eskandari, Hazim Allos, Basmah S. Al Dulaijan, Gandolina Melhem, Ina Sulkaj, Juliano B. Alhaddad, Anis J. Saad, Christa Deban, Philip Chu, John Y. Choi, Branislav Kollar, Bohdan Pomahac, Leonardo V. Riella, Stefan P. Berger, Jan S. F. Sanders, Judy Lieberman, Li Li, Jamil R. Azzi

Summary: Regulatory T cells (T-regs) have shown promise as cellular therapy for various immune diseases, but their clinical efficacy is limited by poor in vivo homeostasis. In this study, inhibiting mTORC1 effectively reduced intracytoplasmic expression and functionality of GrB in host T-regs, leading to decreased apoptosis and improved stability and homeostasis of T-regs.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

mTORC1 regulates a lysosome-dependent adaptive shift in intracellular lipid species

Aaron M. Hosios, Meghan E. Wilkinson, Molly C. McNamara, Krystle C. Kalafut, Margaret E. Torrence, John M. Asara, Brendan D. Manning

Summary: Inhibition of mTORC1 leads to accumulation of intracellular triglycerides through lysosome-dependent hydrolysis of phospholipid fatty acids. The liberated fatty acids can be used for triglyceride synthesis or beta-oxidation.

NATURE METABOLISM (2022)

Add to Collection

Article Medicine, Research & Experimental

GATOR2-dependent mTORC1 activity is a therapeutic vulnerability in FOXO1 fusion-positive rhabdomyosarcoma

Jacqueline Morales, David Allegakoen, Jose A. Garcia, Kristen Kwong, Pushpendra K. Sahu, Drew A. Fajardo, Yue Pan, Max A. Horlbeck, Jonathan S. Weissman, W. Clay Gustafson, Trever G. Bivona, Amit J. Sabnis

Summary: The study reveals that loss of GATOR2 complex impairs mTORC1 signaling and cell cycle transition in FOXO1 fusion-positive rhabdomyosarcoma (RMS). Suppression of GATOR2 inhibits tumor growth and favors the outgrowth of cells lacking PAX3-FOXO1. Genetic activation of mTORC1 can compensate for the loss of certain GATOR2 members. RAS mutations can decouple mTORC1 activation from GATOR2, resulting in aa-independent mTORC1 activity in fusion-negative RMS. A bisteric, mTORC1-selective small molecule induces tumor regressions in fusion-positive patient-derived tumor xenografts.

JCI INSIGHT (2022)

Add to Collection

Article Cell Biology

The crosstalk between MYC and mTORC1 during osteoclastogenesis

Seyeon Bae, Brian Oh, Jefferson Tsai, Peter Sang Uk Park, Matthew Blake Greenblatt, Eugenia G. Giannopoulou, Kyung-Hyun Park-Min

Summary: Osteoclast differentiation and bone resorption activity are regulated by the mTORC1 signaling pathway. This study reveals that MYC plays a key role in the dynamic activation of mTORC1 during osteoclastogenesis. MYC deficiency inhibits the early activation of mTORC1 and reverses the decreased activity of mTORC1 at the late stage of osteoclastogenesis. Inhibition of mTORC1 activity by rapamycin enhances bone resorption activity in mature osteoclasts. Mechanistically, MYC induces GADD34 expression and suppresses mTORC1 activity during the late phase of osteoclastogenesis.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Add to Collection

Article Oncology

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma

Kevin D. Courtney, Yuanqing Ma, Alberto Diaz de Leon, Alana Christie, Zhiqun Xie, Layton Woolford, Nirmish Singla, Allison Joyce, Haley Hill, Ananth J. Madhuranthakam, Qing Yuan, Yin Xi, Yue Zhang, Jenny Chang, Oluwatomilade Fatunde, Yull Arriaga, Arthur E. Frankel, Sanjeeva Kalva, Song Zhang, Tiffani McKenzie, Oscar Reig Torras, Robert A. Figlin, Brian Rini, Renee M. McKay, Payal Kapur, Tao Wang, Ivan Pedrosa, James Brugarolas

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma

Matthias Begemann, Sebastian M. Waszak, Giles W. Robinson, Natalie Jaeger, Tanvi Sharma, Cordula Knopp, Florian Kraft, Olga Moser, Martin Mynarek, Lea Guerrini-Rousseau, Laurence Brugieres, Pascale Varlet, Torsten Pietsch, Daniel C. Bowers, Murali Chintagumpala, Felix Sahm, Jan O. Korbel, Stefan Rutkowski, Thomas Eggermann, Amar Gajjar, Paul Northcott, Miriam Elbracht, Stefan M. Pfister, Udo Kontny, Ingo Kurth

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Variations in screening and management practices for subsequent asymptomatic meningiomas in childhood, adolescent and young adult cancer survivors

Lisanne C. Verbruggen, Melissa M. Hudson, Daniel C. Bowers, Cecile M. Ronckers, Gregory T. Armstrong, Roderick Skinner, Eelco W. Hoving, Geert O. Janssens, Helena J. H. van der Pal, Leontine C. M. Kremer, Renee L. Mulder

JOURNAL OF NEURO-ONCOLOGY (2020)

Add to Collection

Article Oncology

Margin-Free Fractionated Stereotactic Radiation Therapy for Pediatric Brain Tumors

Osama Mohamad, Zabi Wardak, Daniel C. Bowers, Anh H. Le, Tu Dan, Ramzi Abdulrahman, Lynn Gargan, Laura Klesse, Bradley Weprin, Dale Swift, Angela Price, Chuxiong Ding, Strahinja Stojadinovic, Frederick Sklar, Bruno Braga, Robert Timmerman

PRACTICAL RADIATION ONCOLOGY (2020)

Add to Collection

Review Oncology

Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group

Jason Fangusaro, Olaf Witt, Pablo Hernaiz Driever, Asim K. Bag, Peter de Blank, Nadja Kadom, Lindsay Kilburn, Robert M. Lober, Nathan J. Robison, Michael J. Fisher, Roger J. Packer, Tina Young Poussaint, Ludmila Papusha, Shivaram Avula, Alba A. Brandes, Eric Bouffet, Daniel Bowers, Anton Artemov, Murali Chintagumpala, David Zurakowski, Martin van den Bent, Brigitte Bison, Kristen W. Yeom, Walter Taal, Katherine E. Warren

LANCET ONCOLOGY (2020)

Add to Collection

Article Cell Biology

De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection

Daria Beshnova, Jianfeng Ye, Oreoluwa Onabolu, Benjamin Moon, Wenxin Zheng, Yang-Xin Fu, James Brugarolas, Jayanthi Lea, Bo Li

SCIENCE TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Oncology

DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells

Jiil Chung, Yosef E. Maruvka, Sumedha Sudhaman, Jacalyn Kelly, Nicholas J. Haradhvala, Vanessa Bianchi, Melissa Edwards, Victoria J. Forster, Nuno M. Nunes, Melissa A. Galati, Martin Komosa, Shriya Deshmukh, Vanja Cabric, Scott Davidson, Matthew Zatzman, Nicholas Light, Reid Hayes, Ledia Brunga, Nathaniel D. Anderson, Ben Ho, Karl P. Hodel, Robert Siddaway, A. Sorana Morrissy, Daniel C. Bowers, Valerie Larouche, Annika Bronsema, Michael Osborn, Kristina A. Cole, Enrico Opocher, Gary Mason, Gregory A. Thomas, Ben George, David S. Ziegler, Scott Lindhorst, Magimairajan Vanan, Michal Yalon-Oren, Alyssa T. Reddy, Maura Massimino, Patrick Tomboc, An Van Damme, Alexander Lossos, Carol Durno, Melyssa Aronson, Daniel A. Morgenstern, Eric Bouffet, Annie Huang, Michael D. Taylor, Anita Villani, David Malkin, Cynthia E. Hawkins, Zachary F. Pursell, Adam Shlien, Thomas A. Kunkel, Gad Getz, Uri Tabori

Summary: This study identified a new association between loss of polymerase proofreading and MSI, especially when both components are lost. Analysis of indels in microsatellites revealed five distinct signatures, providing insight into the mechanism of indel formation. The research demonstrates that MS-sigs can be a powerful clinical tool for diagnosing replication repair deficiency and predicting immunotherapy response.

CANCER DISCOVERY (2021)

Add to Collection

Article Oncology

Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma

Rahul Kumar, Kyle S. Smith, Maximilian Deng, Colt Terhune, Giles W. Robinson, Brent A. Orr, Anthony P. Y. Liu, Tong Lin, Catherine A. Billups, Murali Chintagumpala, Daniel C. Bowers, Timothy E. Hassall, Jordan R. Hansford, Dong Anh Khuong-Quang, John R. Crawford, Anne E. Bendel, Sridharan Gururangan, Kristin Schroeder, Eric Bouffet, Ute Bartels, Michael J. Fisher, Richard Cohn, Sonia Partap, Stewart J. Kellie, Geoffrey McCowage, Arnold C. Paulino, Stefan Rutkowski, Gudrun Fleischhack, Girish Dhall, Laura J. Klesse, Sarah Leary, Javad Nazarian, Marcel Kool, Pieter Wesseling, Marina Ryzhova, Olga Zheludkova, Andrey Golanov, Roger E. McLendon, Roger J. Packer, Christopher Dunham, Juliette Hukin, Maryam Fouladi, Claudia C. Faria, Jose Pimentel, Andrew W. Walter, Nada Jabado, Yoon-Jae Cho, Sebastien Perreault, Sidney E. Croul, Michal Zapotocky, Cynthia Hawkins, Uri Tabori, Michael D. Taylor, Stefan M. Pfister, Paul Klimo, Frederick A. Boop, David W. Ellison, Thomas E. Merchant, Arzu Onar-Thomas, Andrey Korshunov, David T. W. Jones, Amar Gajjar, Vijay Ramaswamy, Paul A. Northcott

Summary: The study investigated clinical outcomes of relapsed medulloblastoma and compared molecular features between patient-matched diagnostic and relapsed tumors. Results showed variations in molecular subgroup performance and survival status at relapse.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Daniel C. Bowers, Lisanne C. Verbruggen, Leontien C. M. Kremer, Melissa M. Hudson, Roderick Skinner, Louis S. Constine, Noah D. Sabin, Ranjeev Bhangoo, Riccardo Haupt, Mike M. Hawkins, Helen Jenkinson, Raja B. Khan, Paul Klimo Jr, Pieter Pretorius, Antony Ng, Raoul C. Reulen, Cecile M. Ronckers, Zsila Sadighi, Katrin Scheinemann, Netteke Schouten-van Meeteren, Elaine Sugden, Jop C. Teepen, Nicole J. Ullrich, Andrew Walter, W. Hamish Wallace, Kevin C. Oeffinger, Gregory TArmstrong, Helena J. H. van der Pal, Renee L. Mulder

Summary: Exposure to cranial radiotherapy is associated with an increased risk of subsequent CNS neoplasms among childhood, adolescent, and young adult (CAYA) cancer survivors. Surveillance for subsequent neoplasms is important, but there is currently insufficient evidence to establish whether early detection reduces morbidity and mortality. More research is needed to inform survivorship care.

LANCET ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

In Vivo Estimation of Ketogenesis Using Metabolic Flux Analysis-Technical Aspects and Model Interpretation

Stanislaw Deja, Blanka Kucejova, Xiaorong Fu, Jeffrey D. Browning, Jamey D. Young, Shawn Burgess

Summary: The process of ketogenesis in the liver mitochondria and the measurement methods of endogenous ketone production in vivo using tracer approaches are discussed in the study. A two-pool model with simultaneous regression of liquid chromatography-tandem mass spectrometry ketone isotopologues and tracer infusion rates was implemented, along with H-1 NMR monitoring for AcAc tracer and analyte stability to ensure accurate flux calculations. The approach quantified AcAc and BHB pool sizes and their rates of appearance, disposal, and exchange, providing confidence intervals and detecting potential errors in experimental data, with complications for the physiological interpretation of individual ketone fluxes also discussed.

METABOLITES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency

Anirban Das, Sumedha Sudhaman, Daniel Morgenstern, Ailish Coblentz, Jiil Chung, Simone C. Stone, Noor Alsafwani, Zhihui Amy Liu, Ola Abu Al Karsaneh, Shirin Soleimani, Hagay Ladany, David Chen, Matthew Zatzman, Vanja Cabric, Liana Nobre, Vanessa Bianchi, Melissa Edwards, Lauren C. Sambira Nahum, Ayse B. Ercan, Arash Nabbi, Shlomi Constantini, Rina Dvir, Michal Yalon-Oren, Gadi Abebe Campino, Shani Caspi, Valerie Larouche, Alyssa Reddy, Michael Osborn, Gary Mason, Scott Lindhorst, Annika Bronsema, Vanan Magimairajan, Enrico Opocher, Rebecca Loret De Mola, Magnus Sabel, Charlotta Frojd, David Sumerauer, David Samuel, Kristina Cole, Stefano Chiaravalli, Maura Massimino, Patrick Tomboc, David S. Ziegler, Ben George, An Van Damme, Nobuko Hijiya, David Gass, Rose B. McGee, Oz Mordechai, Daniel C. Bowers, Theodore W. Laetsch, Alexander Lossos, Deborah T. Blumenthal, Tomasz Sarosiek, Lee Yi Yen, Jeffrey Knipstein, Anne Bendel, Lindsey M. Hoffman, Sandra Luna-Fineman, Stefanie Zimmermann, Isabelle Scheers, Kim E. Nichols, Michal Zapotocky, Jordan R. Hansford, John M. Maris, Peter Dirks, Michael D. Taylor, Abhaya Kulkarni, Manohar Shroff, Derek S. Tsang, Anita Villani, Wei Xu, Melyssa Aronson, Carol Durno, Adam Shlien, David Malkin, Gad Getz, Yosef E. Maruvka, Pamela S. Ohashi, Cynthia Hawkins, Trevor J. Pugh, Eric Bouffet, Uri Tabori

Summary: This study reports on the effectiveness of ICI treatment in children with tumors caused by germline DNA replication repair deficiency. It shows that high mutation burden and microsatellite load are important predictors of sustained response and long-term survival following PD-1 blockade.

NATURE MEDICINE (2022)

Add to Collection

Review Oncology

Facts and Hopes for Immunotherapy in Renal Cell Carcinoma

Chen Yao, Tian Zhang, Tuoqi Wu, James Brugarolas

Summary: Immunotherapy has had a significant impact on renal cell carcinoma (RCC). Combining anti-angiogenic agents with immune checkpoint inhibitors has transformed patient outcomes. The challenges now include patient selection, resistance mechanisms, and optimizing treatment sequencing. Further research may pave the way for the next generation of therapies.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Clinical Neurology

Consensus Recommendations for Managing Childhood Cancer Survivors at Risk for Stroke After Cranial Irradiation A Delphi Study

Lisa B. Kenney, Bethany L. Ames, Mary S. Huang, Torunn Yock, Daniel C. Bowers, Larissa Nekhlyudov, David Williams, Melissa M. Hudson, Nicole J. Ullrich

Summary: This study used a consensus-building methodology to develop expert recommendations for stroke management in childhood cancer survivors. Despite the lack of evidence, these consensus recommendations and rationale are helpful for clinical decision-making.

NEUROLOGY (2022)

Add to Collection

Article Oncology

Cell Competition Shapes Metastatic Latency and Relapse

Kangsan Kim, Huocong Huang, Pravat Kumar Parida, Lan He, Mauricio Marquez-Palencia, Tanner C. Reese, Payal Kapur, James Brugarolas, Rolf A. Brekken, Srinivas Malladi

Summary: Cell competition leads to the displacement of latent metastatic cells from the primary tumor, with disruption of this process resulting in reduced metastatic incidence. Kidney cancer has enriched tumor subclones with latent metastatic traits, which are associated with rapid onset of metastases and reduced disease-free survival. The findings highlight the importance of cell competition in shaping metastatic latency and relapse.

CANCER DISCOVERY (2023)

Add to Collection

Article Oncology

Phase II study of everolimus for recurrent or progressive pediatric ependymoma

Daniel C. Bowers, Veena Rajaram, Matthias A. Karajannis, Sharon L. Gardner, Jack Meng-Fen Su, Patricia Baxter, Sonia Partap, Laura J. Klesse

Summary: This phase II clinical trial evaluated the efficacy of everolimus, an mTOR pathway inhibitor, for children with recurrent or progressive posterior fossa-A (PF-A) ependymomas. The study showed that everolimus did not lead to objective tumor responses in these patients. Adverse events were generally mild, with only one case of grade 3 pneumonia.

NEURO-ONCOLOGY ADVANCES (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.